Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Lilotomab |
Synonyms | |
Therapy Description |
Lilotomab is a murine antibody that targets CD37, which potentially results in enhanced antibody-dependent cell-mediated cytotoxicity response against tumor cels expressing CD37 (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Lilotomab | HH1 | CD37 Antibody 8 | Lilotomab is a murine antibody that targets CD37, which potentially results in enhanced antibody-dependent cell-mediated cytotoxicity response against tumor cels expressing CD37 (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01796171 | Phase Ib/II | Lilotomab Betalutin Rituximab | A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01) | Completed | USA | TUR | SWE | POL | NOR | NLD | ITA | ISR | IRL | HUN | HRV | GBR | FRA | FIN | ESP | DNK | CZE | CHE | CAN | BEL | AUT | AUS | 2 |